* Says it has been granted approval for chemical drug clinical trials for XY0206 API and tablet issued by china food and drug administration

* XY0206 is used for treatment of leukemia and lung cancer and other malignant tumors

Source text in Chinese: goo.gl/iX5rJu

Further company coverage: (Beijing Headline News)